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CARRAGEENAN has  been  widely  used  as  an  irritant  to
evoke  inflammation  in  animals  or  to  selectively
deplete macrophages in vivo. Although precise under-
standing of carrageenan activity is a prerequisite for
the  experimental  use  of  this  polysaccharide,  the
effects  of  this  agent  on  host-biological  systems  are
still poorly understood. We investigated the effect of
carrageenan on serum concentrations of complement
C3  and  interleukin  (IL)-6,  a  potent  complement-
inducing  factor.  Intraperitoneal  administration  of
carrageenan (4 mg) in mice resulted in an initial fall
in serum C3 (70% of control, P < 0.05) between 3 and
6 h, but was followed by a significant rise (180% of the
control,  P <  0.05)  at  24 h.  Prior  to  the  rise  in
complement  C3,  a  sharp  peak  of  serum  IL-6  was
observed  at  6 h  after  carrageenan  treatment.  These
results indicate potential of carrageenan to enhance
host complement systems, which may be associated
with, at least in part, an acute induction of IL-6.
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Introduction
Carrageenan  is  a  high-molecular-weight  sulphated
polygalactose  obtained  from  marine  plants.1 This
polysaccharide exerts a variety  of activities in host
biological  systems,  such  as  cytotoxicity  to  macro-
phages,2 activation of Hageman factor3 and inhibition
of complement.4,5 In experimental conditions, carra-
geenan  has  been  widely  used  as  a  tool  to  evoke
inflammation in animals6,7 or to produce a selective
depletion of macrophages in vivo.8–10Therefore, for a
correct interpretation of the results of experiments
using carrageenan, it is necessary to consider all the
possible effects of this polysaccharide on host biolog-
ical systems.
In  1965,  Davies5 reported  that  carrageenan  pre-
vented the reaction of complement with sensitized
red blood cells, probably by a direct inactivation of
the complement. However, since then, no study has
quantitatively measured the effect of carrageenan on
serum  complement  levels.  Recently,  several  inves-
tigators have reported that carrageenan may poten-
tially modulate the production of inflammatory cyto-
kines  such  as  interleukin-1  (IL-1),  IL-6  and  tumour
necrosis factor (TNF).11–13 Since these cytokines are
known to play a critical role in inducing acute phase
proteins including complement,14 we speculate that
carrageenan  may  influence  the  host-complement
system not only through direct inactivation of com-
plement, but also production of these cytokines.
In the present study we examined the kinetics of
serum concentrations of complement C3 and IL-6, a
potent complement-inducing factor, following intra-
peritoneal administration of carrageenan in mice.
Materials and Methods
Animals
Specific-pathogen-free male ICR mice (6 weeks old)
were purchased from Charles River Japan (Kanagawa,
Japan).  They  were  housed  in  groups  of  10  and
provided with food and water ad libitum.
Administration of carrageenan
Iota-carrageenan (Sigma, St Louis, MO) was dissolved
in pyrogen-free physiological saline, and autoclaved at
121°C for 15min before use. ICR mice were injected
intraperitoneally  with  4mg  of  carrageenan  per
mouse. The dose of carrageenan used in this study
was equivalent to that used by other investigators to
deplete  macrophages.9 Mice  were  sacrificed  in  an
ether-saturated chamber 0, 3, 6, 12, 24 and 48h after
the injection of carrageenan. Blood was collected by
cardiocentesis and allowed to clot at 4°C for 2h and
centrifuged  to  obtain  serum,  which  was  stored  in
aliquots at –80°C before assay for complement C3 and
IL-6.
Assay of serum complement C3 and IL-6
Serum concentrations of complement C3 were deter-
mined by Behring Nephelometer Analyzer (Behring
Berke, Marburg, Germany) using anti-murine comple-
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PA). The  concentration  of  murine  serum  IL-6  was
quantified using a sandwich-type ELISA according to
the instructions provided by the manufacturer (Endo-
gen,  Boston, MA). A reference  curve  was  obtained
using recombinant mouse IL-6 and the assay had a
limited sensitivity of 15pg/ml.
Statistical analysis
Data  were  expressed  as  mean  ±  SD.  Differences
between  groups  were  tested  for  statistical  signifi-
cance using the Student’s t-test. A P value £ 5%  was
accepted as statistically significant.
Results and Discussion
As shown in Fig. 1a, carrageenan induced a biphasic
response of serum concentrations of complement C3.
This was characterized by a fall (approximately 70%
of the control, P<0.05) at 3–6h followed by a rise
(approximately 180% of the control, P<0.05) in serum
concentration 24h after administration. Although it is
well  known  that  carrageenan  suppresses  the  cell-
lysing  activity  of  complement  in  vitro,4,5 our  data
showed  for  the  first  time  that  carrageenan  may
potentially enhance the host complement system in
vivo.
The complement system plays an important role in
inflammatory and host immunological processes. In
particular, complement C3 is a critical component for
opsonization,  cell-lysis  activity  and  chemotaxis. To
assess the function of the complement system, it may
be  necessary  to  analyse  quantitatively  the  level  of
each  complement  component. Although  this  poly-
saccharide is known to induce an immunocompro-
mised state by its macrophage-blocking activity,2 our
data suggest that carrageenan may augment comple-
ment-mediated  host  defence  systems.  Indeed,  Iri-
fune15 reported  that  carrageenan  treatment  (24h
before and 48h after infection) significantly improved
the  survival  of  mice  with  pneumonia  using  an
inhalation model of Klebsiella pneumonia. We also
observed that intraperitoneal administration of carra-
geenan 24h before induction of pleurisy enhanced
the  chemotactic  response  in  the  pleural  cavity  of
mice.12These results and the present data suggest that
carrageenan  may  modulate  complement-mediated
inflammatory and immunological responses produc-
ing an initial suppression followed by enhancement of
C3.
Recent studies have indicated that administration of
carrageenan  in  vivo influences  the  production  of
inflammatory cytokines (e.g. IL-1, IL-6 and TNF).11–13
These cytokines are important mediators not only for
activation of immune cells but also for the induction
of acute phase proteins, such as C-reactive protein,
serum amyloid A and complements.14As shown in Fig.
1b, a sharp peak of serum IL-6 was observed 6h after
intraperitoneal  administration  of  carrageenan.  Our
data were to a large extent consistent with a previous
report by Utsunomiya et al.13 in which  a transient
peak of serum IL-6 was observed 4h after intrapleural
inoculation of carrageenan in rats. They also showed
that treatment with carrageenan resulted in a marked
increase in serum concentrations of T -kininogen, an
acute phase protein, at 16h, although an initial fall in
the  concentration  was  not  demonstrated.  In  the
present  study,  the  time-lag  between  peak  IL-6  and
peak complement C3 was 18h, which is considerably
similar to that of T -kininogen in the rat pleurisy model.
It is most likely that carrageenan-induced IL-6 produc-
tion may explain at least in part the rise of comple-
ment C3 in the later phase.
In  conclusion,  the  present  results  indicate  that
carrageenan may potentially enhance the host com-
plement system, which may be mediated by an acute
induction of IL-6 production. Thus, our data suggest a
novel  effect  for carrageenan on the host biological
system.
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FIG. 1. Changes in serum concentrations of complement C3 (A) and IL-6 (B) in mice treated with intraperitoneal carrageenan.
*P<0.05 compared with the control (time = 0). Data are mean ± SD of five mice.References
1. Di  Rosa  M.  Biological  properties of  carrageenan.  J  Pharm  Pharmac
1972;  24: 89–102.
2. Catanzaro  PJ,  Schwartz  HJ,  Graham  RC.  Spectrum  and  possible
mechanism  of  carrageenan  cytotoxicity.  Am  J  Pathol 1971;  64:
387–399.
3. Schwartz HJ, Kellermeyer RW . Carrageenan and delayed hypersensitiv-
ity.  II. Activation  of  Hageman  factor  by  carrageenan and  its  possible
significance. Proc Soc Exp Biol Med 1969;  132: 1021–1024.
4. Boros T , Rapp HJ, Crisler CJ. The interaction between carrageenan and
the  first  component  of  complement.  J  Immunol 1965;  94:
662–666.
5. Davies GE. Inhibition of complement by carrageenan: mode of action,
effect  on  allergic  reactions  and  on  complement  of  various  species.
Immunology 1965;  8: 291–299.
6. Bianchi  M, Bloom O, Raabe T , et al. Suppression of proinflammatory
cytokines in monocytes by a tetravalent guanylhydrazone.  J Exp Med
1996;  183: 927–936.
7. Meyers  KP ,  Czachowski  CL,  Coffey  JW .  Effect  of  treatment  with
interleukin-1 receptor antagonist on the development of carrageenan-
induced pleurisy in rat. Inflammation 1993;  17: 121–134.
8. Abd AHA, Savage NW , Halliday WJ, Hume DA. The role of macrophages
in experimental arthritis induced by Streptococcus agalactiae sonicate:
actions  of  macrophage  colony-stimulating  factor  (CSF-1)  and  other
macrophage-modulating  agents.  Lymphokine  Cytokine  Res 1991;  10:
43–50.
9. Nanno M, Shimizu T , Mike A, Ohwaki M, Mutai M. Role of macrophages
in serum colony-stimulating factor induction by Lactobacillus casei in
mice. Infect Immun 1988; 56: 357–362.
10. Zhang  W ,  Arii  S,  Sasaoki T ,  et  al. The  role  of  kupffer  cells  in  the
surveillance  of  tumor  growth  in  the  liver.  J  Surg  Res 1993;  55:
140–146.
11. Ogata M, Yoshida S, Kamochi M, Shigematsu A, Mizuguchi Y. Enhance-
ment of lipopolysaccharide-induced tumor necrosis factor production in
mice by carrageenan pretreatment. Infect Immun 1991; 59: 679–683.
12. Tateda K, Irifune K, Shimoguchi K, et al.Potential activity of carrageenan
to enhance antibacterial host-defense systems in mice. J Infect Chem-
other 1995; 1: 59–63.
13. Utsunomiya I, Nagai S, Oh-ishi S. Sequential appearance of IL-1 and IL-6
activities  in rat  carrageenan-induced pleurisy.  J  Immunol 1991;  147:
1803–1809.
14. Moshage H. Cytokines and the hepatic acute phase response. J Pathol
1997; 181: 257–266.
15. Irifune K. Alveolar destruction in experimental Klebsiella pneumonia.
Acta Pathol Jpn 1987; 37: 475–486.
ACKNOWLEDGEMENTS. We thank Dr S. Kuwahara for the critical reading of
the manuscript and his helpful suggestions. We also thank Dr F . G. Issa for
expert editorial assistance.
Received 28 January 1998;
accepted 9 March 1998
Biphasic changes of serum C3 by carrageenan
Mediators of Inflammation · Vol 7 · 1998 223